ABSTRACT
BACKGROUND: Kawasaki disease is the leading cause of acquired heart disease in childhood. However, there are only a few reports in infants younger than 6 months. The objective of this study is to investigate the clinical and laboratory characteristics of Kawasaki disease in infants younger than 6 months. METHODS: From 1994 to 2003, 120 patients with Kawasaki disease diagnosed at our institution were included. Group 1 consisted of 20 (17%) patients younger than 6 months, and group 2 consisted of 100 (83%) patients older than 6 months. Clinical manifestations, laboratory results, echocardiographic findings, treatment and outcome were compared between these 2 groups. RESULTS: Clinical manifestations (hydrops of gallbladder: 0% versus 16%, P < 0.001) and laboratory results (white blood cell count 21,740 +/- 11,706 versus 11,830 +/- 4390/mm3, P < 0.001; hemoglobin 9.98 +/- 1.25 versus 10.8 +/- 1.37 g/dL, P = 0.015; platelet 483 +/- 393 versus 355 +/- 138 x 1000/mm3, P = 0.011; triglyceride 138 +/- 77.5 versus 107 +/- 17 mg/dL, P < 0.001) were different between patients with Kawasaki disease younger and older than 6 months, respectively. Younger infants were more likely to have incomplete presentation (35% versus 12%, P = 0.025), coronary involvement (65% versus 19%, P < 0.001), late intravenous immunoglobulin treatment and relatively poor outcome. CONCLUSIONS: Infants younger than 6 months with prolonged unexplained febrile illnesses should be suspected as having Kawasaki disease, despite the incomplete clinical presentation. Because early diagnosis and timely treatment are difficult in younger infants with Kawasaki disease because of delayed and incomplete clinical presentations, echocardiogram becomes an important implement for diagnosis. Early intravenous immunoglobulin treatment is required in view of the highest risk of coronary involvement in them.
Subject(s)
Cardiovascular Diseases/etiology , Mucocutaneous Lymph Node Syndrome/complications , Mucocutaneous Lymph Node Syndrome/physiopathology , Age Factors , Age of Onset , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/therapeutic use , Child , Child, Preschool , Female , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Incidence , Infant , Male , Mucocutaneous Lymph Node Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/therapy , Treatment OutcomeABSTRACT
Plasma electrolyte concentrations in premature infants are unstable, and hyperkalemia may induce significant, even life-threatening, symptoms in tiny infants. The medical records of 95 premature infants were retrospectively reviewed. Patients with a major congenital anomaly or mortality within 24 h after birth were excluded. Plasma electrolytes, blood urea nitrogen, creatinine, blood pH, urine output, and related clinical conditions during first 96 h of life were analyzed. Plasma potassium concentrations had significant negative correlations with gestational age and birth weight (p < 0.05). Infants with a gestational age of less than 29 weeks had significantly higher potassium concentrations (average 5.9 +/- 0.3 mEq/L, peak 7.8 +/- 0.4 mEq/L, p < 0.05) than other gestational age groups, and their plasma potassium levels were significantly higher at 24 and 48 h of age (p < 0.05). Forty-two infants (42/95, 44%) had peak plasma potassium concentrations greater than or equal to 6 mEq/L. With statistical analysis, the hyperkalemic infants comprised of significantly (p < 0.05) fewer males (31% vs. 55%), they had more-severe respiratory distress syndrome (RDS) (grades 2 +/- 0 vs. 1 +/- 0, p < 0.05), and needed more frequent use of inotropics (52% vs. 23%, p < 0.05) compared to normokalemic infants. In conclusion, hyperkalemia during the first 2 days of life is common in extremely premature infants. Small gestational age, very low birth weight, female gender, high RDS grade, need of exogenous surfactant and inotropic agents, delayed feeding, and a high mortality rate were observed in hyperkalemic infants.
